electroCore Announces Changes to its Board of Directors
09 Março 2022 - 1:30PM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine company, today announced the appointment of Julie Bruzzone
Goldstein and Tricia Wilber to the company’s Board of Directors
effective March 15, 2022. The Company also announced that effective
March 4, 2022, Dr. Stephen Ondra is resigning from the Board to
focus on his new role as Chief Medical Advisor at MITRE, and
Michael Atieh will not be standing for re-election to the Board at
the 2022 Annual General Meeting.
“Ms. Goldstein and Ms. Wilber are successful business leaders
with proven track records, and I am pleased to welcome them to our
Board,” said Peter Cuneo, Chairman of the Board of Directors of
electroCore. “As the company continues to invest in
direct-to-consumer initiatives, their breadth of knowledge and
experience will add significant value as we seek to expand the
reach and impact of our therapies. These appointments are great
additions to our Board of Directors, and we look forward to their
contributions.”
Mr. Cuneo continued, “I would like to recognize and thank Mr.
Atieh and Dr. Ondra for their long service and myriad contributions
to the Company. Their leadership and dedication, Mr. Atieh’s role
as our previous Chairman, and both Directors’ service on various
committees, have greatly advanced our business. Both Mr. Atieh and
Dr. Ondra will remain available to the Company as advisors to the
Chairman and CEO. We wish them continued success in their future
endeavors.”Ms. Goldstein brings to electroCore more than 30 years
of leadership expertise in product, media and entertainment
marketing, which spans a career in radio, television, music and
theater. Ms. Goldstein’s specific expertise includes operations,
sales development, advertising, and project management. She has
also spearheaded many major national and international marketing
campaigns. She worked as a Broadway producer for the musical, First
Date, and served in senior marketing positions, artist development
and media-sales at JIVE Records, TV Guide Television Network, RCA
Records, Virgin Records and multiple radio stations. As a key
player, her expertise around spending and strategic marketing
techniques contributed to RCA’s turnaround. She received the
Billboard Magazine’s Radio Promotion Director of the Year,
Bertelsmann Key Management Award, and Virgin Records Promotion
Director of the Year. Ms. Goldstein holds a Bachelor of Arts in
Communications and Social Welfare from California State University
at Chico.
During her distinguished career, Ms. Wilber has been a Chief
Marketing Officer, global business strategist, and board member who
delivers organizational and cultural transformation for branding.
She is a pioneer in new franchise models and branded partnerships.
Ms. Wilber last served as the Executive Vice President, CMO, and
Managing Director of Partnerships, EMEA, the highest position in
the marketing department at Disney, where she drove growth for Walt
Disney Company’s marquee brands by leading marketing and
communications for Disney, Pixar, Star Wars, and Marvel.
Additionally, she established and led EMEA’s 40-country integrated
marketing, franchise and partnership functions, including a major
reorganization of the EMEA channels to boost growth and
profitability by significantly reducing expenses. She served as a
Director for the board of Euro Disney SCA, and served as a member
of the board of directors of Magical Cruise Company, more commonly
known as Disney Cruise Line. Ms. Wilber holds a Bachelor of Arts in
History from Brown University.
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine company dedicated to
improving patient outcomes through its non-invasive vagus nerve
stimulation therapy platform, initially focused on the treatment of
multiple conditions in neurology. The company's current indications
are the preventive treatment of cluster headache and migraine, the
acute treatment of migraine and episodic cluster headache, the
acute and preventive treatment of migraines in adolescents, and
paroxysmal hemicrania and hemicrania continua in adults.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans (including with respect to enrollment in
ongoing studies); its pipeline or potential markets for its
technologies; the timing, outcome and impact of regulatory,
clinical and commercial developments including online, e-commerce,
direct-to-consumer channels, telehealth portal, and cash pay
initiatives; the issuance of U.S. and international patents
providing expanded IP coverage; the possibility of future business
models and revenue streams from the company’s potential use of nVNS
for the acute treatment of PTSD, stroke and hemorrhagic brain
injury, the potential of nVNS generally and gammaCore in particular
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "believes," "intends," other words of similar
meaning, derivations of such words and the use of future dates.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to raise the additional funding
needed to continue to pursue electroCore’s business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, the ability to
commercialize gammaCore™, the potential impact and effects of
COVID-19 on the business of electroCore, electroCore’s results of
operations and financial performance, and any measures electroCore
has and may take in response to COVID-19 and any expectations
electroCore may have with respect thereto, competition in the
industry in which electroCore operates and overall market
conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents electroCore files with the SEC available at
www.sec.gov.
For more information, visit www.electrocore.com.
Investors:Rich CockrellCG
Capital404-736-3838ecor@cg.capitalorMedia
Contact:Jackie
DorskyelectroCore908-313-6331Jackie.dorsky@electrocore.com
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024